Effect of atorvastatin on different fibrinolyis mechanisms in hypercholesterolemic subjects

Background: Hydroxymethyl-glutaryl-CoA-reductase inhibitors (statins) reduce cardiovascular events by cholesterol lowering as well as non-lipid related actions. Among them, the modulation of fibrinolysis could play a relevant role in vascular protection. Atorvastatin is able of reducing platelet activity and thrombin generation before low-density lipoprotein cholesterol (LDL-C) decrease in hypercholesterolemic subjects in which coagulation and fibrinolysis are linked by the activation of thrombin activable fibrinolysis inhibitor (TAFI). The aim of our study was to evaluate whether atorvastatin could modulate fibrinolysis by interactions with endothelial mechanisms and thrombin generation. Methods: Forty-four pure hypercholesterolemic subjects (26 M, 18 F, mean age 52.7 +/- 13.7, LDL-C 194.8 +/- 9.3t mg/dl) were evaluated for plasmin-antiplasmin complexes (PAP), tissue-plasminogen acivator (t-PA) and its inhibitor (PA1-1) (ELISA), TAFI activity (HPLC), platelet P-selectin (P-sel) (cytofluorymetric detection), platelet-dependent thrombin generation (PDTG, coagulative-chromogenic method) and lipid profile at baseline and after 7, 14, 28 and 90 days of atorvastatin (10 mg/die) treatment. Results: PAP were significantly reduced at baseline in hypercholesterolemic versus control subjects (P < 0.05) and were related to P-sel (P < 0.01), PDTG (P < 0.01) and its inhibitor (PAI-1) after venous occlusion (VO) (P < 0.05). Atorvastatin induced a significant increase of PAP at T-2 related to modifications of P-sel (P < 0.01) and PDTG (P < 0.01) before significant LDL-C reduction (P = 0.132). PAI-I was significantly changed at 73 with relation to LDL-C (P < 0.01), Von Willebrand factor (VWF) (P < 0.01) and sE-sel (P < 0.05). Conclusions: The profibrinolytic activity of atorvastatin in hypercholesterolemic subjects is related, initially, to the positive effects exerted on platelet function and thrombin generation which can modulate fibrinolysis by TAFI activity. (C) 2003 Elsevier Ireland Ltd. All rights reserved.